Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Stintzing

Showing results (161-170 of 206) with videos related to

Pageof 21
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF<sup>V600E</sup>-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)Lena Weiss, Sebastian Stintzing, Dominik Paul Modest, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Amphiregulin Expression Is a Predictive Biomarker for <i>EGFR</i> Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized TrialsArndt Stahler, Sebastian Stintzing, Dominik P Modest, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2021
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)Kathrin Heinrich, Dominik P Modest, Ingrid Ricard, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2025
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trialKathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Plos One|March 10, 2018
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patientsMarta Schirripa, Wu Zhang, Dongyun Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2021
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)Arndt Stahler, Volker Heinemann, Veronika Schuster, et al.
BMC Cancer|April 3, 2022
FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancerNathanael Raschzok, Sebastian Stintzing, Volker Heinemann, et al.
British Journal of Cancer|November 6, 2020
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trialVolker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2019
Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3Alberto Puccini, Fotios Loupakis, Sebastian Stintzing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2024
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)Arndt Stahler, Andreas J Kind, Christine Sers, et al.
Pageof 21

Showing results (161-170 of 206) with videos related to

Sort By:
Pageof 21
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF<sup>V600E</sup>-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)Lena Weiss, Sebastian Stintzing, Dominik Paul Modest, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Amphiregulin Expression Is a Predictive Biomarker for <i>EGFR</i> Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized TrialsArndt Stahler, Sebastian Stintzing, Dominik P Modest, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2021
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)Kathrin Heinrich, Dominik P Modest, Ingrid Ricard, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2025
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trialKathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Plos One|March 10, 2018
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patientsMarta Schirripa, Wu Zhang, Dongyun Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2021
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)Arndt Stahler, Volker Heinemann, Veronika Schuster, et al.
BMC Cancer|April 3, 2022
FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancerNathanael Raschzok, Sebastian Stintzing, Volker Heinemann, et al.
British Journal of Cancer|November 6, 2020
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trialVolker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2019
Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3Alberto Puccini, Fotios Loupakis, Sebastian Stintzing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2024
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)Arndt Stahler, Andreas J Kind, Christine Sers, et al.
Pageof 21